Analysts Set Alphatec Holdings, Inc. (NASDAQ:ATEC) Price Target at $17.00

Alphatec Holdings, Inc. (NASDAQ:ATEC) has been given an average rating of “Moderate Buy” by the nine analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $17.00.

Several equities research analysts recently issued reports on ATEC shares. Wells Fargo & Company dropped their price objective on Alphatec from $26.00 to $19.00 and set an “overweight” rating for the company in a research note on Thursday, August 1st. Canaccord Genuity Group reaffirmed a “buy” rating and set a $20.00 price target on shares of Alphatec in a research note on Friday, August 30th. Lake Street Capital dropped their price target on Alphatec from $32.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd. Piper Sandler dropped their price target on Alphatec from $17.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, August 1st. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research note on Thursday, October 31st.

Alphatec Price Performance

ATEC opened at $8.23 on Friday. The firm has a 50-day moving average price of $6.30 and a 200-day moving average price of $8.39. Alphatec has a twelve month low of $4.88 and a twelve month high of $17.34. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The company has a market capitalization of $1.17 billion, a price-to-earnings ratio of -6.43 and a beta of 1.31.

Insider Activity

In other news, Director David M. Demski acquired 50,000 shares of the business’s stock in a transaction dated Wednesday, August 21st. The stock was purchased at an average price of $5.67 per share, for a total transaction of $283,500.00. Following the completion of the transaction, the director now directly owns 288,441 shares in the company, valued at approximately $1,635,460.47. This trade represents a 20.97 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 22.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Magnetar Financial LLC bought a new position in shares of Alphatec in the 2nd quarter valued at about $10,957,000. First Eagle Investment Management LLC bought a new stake in Alphatec in the second quarter worth about $1,071,000. Lighthouse Investment Partners LLC lifted its stake in Alphatec by 257.5% in the second quarter. Lighthouse Investment Partners LLC now owns 208,594 shares of the medical technology company’s stock worth $2,180,000 after purchasing an additional 150,244 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Alphatec by 276.1% in the first quarter. BNP Paribas Financial Markets now owns 99,790 shares of the medical technology company’s stock worth $1,376,000 after purchasing an additional 73,257 shares during the last quarter. Finally, AlphaCentric Advisors LLC bought a new stake in Alphatec in the third quarter worth about $2,057,000. Institutional investors own 66.35% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.